Bladder Cancer, Brain Cancer, Breast Cancer, Cancer of Bone and Connective Tissue, Cancer of Cervix, Cancer of Colon, Cancer of Endometrium, Cancer of Esophagus, Cancer of Gastrointestinal Tract, Cancer of Head and Neck, Cancer of Kidney, Cancer of Larynx, Cancer of Liver, Cancer of Rectum, Cancer of Skin, Cancer of Stomach, Cancer of the Bile Duct, Cancer of Vulva, Fallopian Tube Cancer, Leukemia, Lung Cancer, Lymphoma, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Spinal Cord Cancer
Conditions
Keywords
Cancer, Oncology, Observational, Genomic Profiling, Precision Medicine
Brief summary
Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.
Detailed description
The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment.
Interventions
OTHERObservation
No Intervention
Sponsors
Tempus AI
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
1. Solid or hematologic malignancy. 2. Willing and able to provide informed consent where required. 3. Has received or will receive genomic profiling.
Exclusion criteria
1. Individuals without the capacity to consent. 2. Prisoners at the time of enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Create robust data set of health information | Up to 10 years | To create a robust data set of health information about cancer patients who receive comprehensive genomic profiling in order to facilitate future novel precision medicine research |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Document clinical events for patients who have had comprehensive genomic profiling | Up to 10 years | To document specific clinical events in relation to diagnosis, treatment, and outcomes for patients who have had comprehensive genomic profiling |
| Evaluate longitudinal paired tissue and cell free molecular testing | Up to 10 years | To evaluate the feasibility of longitudinal paired tissue and cell free molecular testing of participants with specific types of cancer, mutations, or therapies |
Other
| Measure | Time frame | Description |
|---|---|---|
| Support prospective and retrospective research studies | Up to 10 years | To support prospective and retrospective research studies on participants with specific cancer types |
| Describe real world treatment outcomes | Up to 10 years | To describe real world treatment outcomes (such as real-world response, real world duration of response, real world progression free survival, real world time to next treatment, real world time to treatment discontinuation, and overall survival) |
| Review medical information for standard of care decisions and health outcomes | Up to 10 years | To review medical information for standard of care decisions in the future and general health outcomes |
Countries
United States
Outcome results
None listed